one month supply of tirzepatide Compounded - Phase 2 - Compounded Tirzepatide (GLP-1/GIP)

Regular check-ins allow us to adjust your plan based on how your body responds

Randomized trials focused on efficacy and common adverse events but were not powered to detect rare thromboembolic events reliably

Semaglutide works on receptors involved in appetite regulation and blood sugar control

This series of phase 3, randomised, double-blind, placebo-controlled clinical trials involved more than 25,000 individuals with overweight or obesity and has extensively demonstrated the efficacy of once-weekly subcutaneous semaglutide 2.4 mg in promoting weight loss [13, 38,39,40,41,42,43,44,45,46]

Implications for marketers: Interest in GLP-1s is highest among consumers diagnosed as overweight or obese, but weight loss isnt always what motivates people to use GLP-1s